annual EBITDA:
-$104.24M-$21.00M(-25.24%)Summary
- As of today (August 22, 2025), ELVN annual EBITDA is -$104.24 million, with the most recent change of -$21.00 million (-25.24%) on December 31, 2024.
- During the last 3 years, ELVN annual EBITDA has fallen by -$79.59 million (-322.92%).
- ELVN annual EBITDA is now -332.82% below its all-time high of -$24.08 million, reached on December 1, 2019.
Performance
ELVN EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly EBITDA:
-$28.50M+$3.12M(+9.85%)Summary
- As of today (August 22, 2025), ELVN quarterly EBITDA is -$28.50 million, with the most recent change of +$3.12 million (+9.85%) on June 30, 2025.
- Over the past year, ELVN quarterly EBITDA has dropped by -$3.98 million (-16.22%).
- ELVN quarterly EBITDA is now -775.13% below its all-time high of -$3.26 million, reached on December 31, 2022.
Performance
ELVN quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBITDA:
-$113.93M-$3.98M(-3.62%)Summary
- As of today (August 22, 2025), ELVN TTM EBITDA is -$113.93 million, with the most recent change of -$3.98 million (-3.62%) on June 30, 2025.
- Over the past year, ELVN TTM EBITDA has dropped by -$16.67 million (-17.14%).
- ELVN TTM EBITDA is now -1557.35% below its all-time high of -$6.87 million, reached on September 1, 2019.
Performance
ELVN TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
ELVN EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -25.2% | -16.2% | -17.1% |
| 3 y3 years | -322.9% | -218.0% | -150.1% |
| 5 y5 years | -332.8% | -177.3% | -365.4% |
ELVN EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -322.9% | at low | -775.1% | +9.8% | -259.0% | at low |
| 5 y | 5-year | -332.8% | at low | -775.1% | +9.8% | -365.4% | at low |
| alltime | all time | -332.8% | at low | -775.1% | +9.8% | -1557.3% | at low |
ELVN EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2025 | - | -$28.50M(-9.9%) | -$113.93M(+3.6%) |
| Mar 2025 | - | -$31.62M(+17.9%) | -$109.95M(+5.5%) |
| Dec 2024 | -$104.24M(+25.2%) | -$26.82M(-0.6%) | -$104.24M(+4.2%) |
| Sep 2024 | - | -$26.99M(+10.0%) | -$100.07M(+2.9%) |
| Jun 2024 | - | -$24.52M(-5.3%) | -$97.25M(+4.8%) |
| Mar 2024 | - | -$25.91M(+14.4%) | -$92.79M(+11.5%) |
| Dec 2023 | -$83.23M(+147.4%) | -$22.65M(-6.3%) | -$83.23M(+30.4%) |
| Sep 2023 | - | -$24.17M(+20.5%) | -$63.84M(+26.3%) |
| Jun 2023 | - | -$20.06M(+22.7%) | -$50.54M(+28.1%) |
| Mar 2023 | - | -$16.35M(+402.0%) | -$39.45M(+24.3%) |
| Dec 2022 | -$33.65M | -$3.26M(-70.0%) | -$31.73M(-25.8%) |
| Sep 2022 | - | -$10.87M(+21.3%) | -$42.79M(-6.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2022 | - | -$8.96M(+3.8%) | -$45.55M(-8.4%) |
| Mar 2022 | - | -$8.64M(-39.6%) | -$49.73M(-3.1%) |
| Dec 2021 | -$24.65M(-40.8%) | - | - |
| Dec 2021 | - | -$14.31M(+4.9%) | -$51.34M(+5.7%) |
| Sep 2021 | - | -$13.63M(+3.7%) | -$48.56M(+2.5%) |
| Jun 2021 | - | -$13.14M(+28.2%) | -$47.40M(+6.4%) |
| Mar 2021 | - | -$10.26M(-11.0%) | -$44.53M(+7.0%) |
| Dec 2020 | -$41.60M(+72.7%) | -$11.53M(-7.6%) | -$41.60M(+38.3%) |
| Sep 2020 | - | -$12.47M(+21.3%) | -$30.07M(+22.9%) |
| Jun 2020 | - | -$10.28M(+40.2%) | -$24.48M(+72.4%) |
| Mar 2020 | - | -$7.33M(+6.6%) | -$14.20M(+106.6%) |
| Dec 2019 | -$24.08M | - | - |
| Sep 2019 | - | -$6.87M | -$6.87M |
FAQ
- What is Enliven Therapeutics, Inc. annual EBITDA?
- What is the all time high annual EBITDA for Enliven Therapeutics, Inc.?
- What is Enliven Therapeutics, Inc. annual EBITDA year-on-year change?
- What is Enliven Therapeutics, Inc. quarterly EBITDA?
- What is the all time high quarterly EBITDA for Enliven Therapeutics, Inc.?
- What is Enliven Therapeutics, Inc. quarterly EBITDA year-on-year change?
- What is Enliven Therapeutics, Inc. TTM EBITDA?
- What is the all time high TTM EBITDA for Enliven Therapeutics, Inc.?
- What is Enliven Therapeutics, Inc. TTM EBITDA year-on-year change?
What is Enliven Therapeutics, Inc. annual EBITDA?
The current annual EBITDA of ELVN is -$104.24M
What is the all time high annual EBITDA for Enliven Therapeutics, Inc.?
Enliven Therapeutics, Inc. all-time high annual EBITDA is -$24.08M
What is Enliven Therapeutics, Inc. annual EBITDA year-on-year change?
Over the past year, ELVN annual EBITDA has changed by -$21.00M (-25.24%)
What is Enliven Therapeutics, Inc. quarterly EBITDA?
The current quarterly EBITDA of ELVN is -$28.50M
What is the all time high quarterly EBITDA for Enliven Therapeutics, Inc.?
Enliven Therapeutics, Inc. all-time high quarterly EBITDA is -$3.26M
What is Enliven Therapeutics, Inc. quarterly EBITDA year-on-year change?
Over the past year, ELVN quarterly EBITDA has changed by -$3.98M (-16.22%)
What is Enliven Therapeutics, Inc. TTM EBITDA?
The current TTM EBITDA of ELVN is -$113.93M
What is the all time high TTM EBITDA for Enliven Therapeutics, Inc.?
Enliven Therapeutics, Inc. all-time high TTM EBITDA is -$6.87M
What is Enliven Therapeutics, Inc. TTM EBITDA year-on-year change?
Over the past year, ELVN TTM EBITDA has changed by -$16.67M (-17.14%)